Crinetics Pharmaceuticals (CRNX) Earnings
Price: $32.39
Market Cap: $3.01B
Market Cap: $3.01B
Revenue (TTM): $1.04M
Net Income: $-298.41M
Net Income: $-298.41M
P/E Ratio: -9.93
EPS (TTM): $-3.26
EPS (TTM): $-3.26
Earnings Dates
Crinetics Pharmaceuticals (CRNX) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 08, 2025
- Time of Day: After Market Close
- Estimated EPS: $-0.99
Last Earnings Report
- Date: February 27, 2025
- EPS: $-0.88
- EPS Estimate: $-0.92
Crinetics Pharmaceuticals's next earnings report is scheduled for May 08, 2025.
In its last earnings report on February 27, 2025, Crinetics Pharmaceuticals reported earnings per share (EPS) of $-0.88, compared to an estimated EPS of $-0.92. The company reported revenue of $-, compared to an estimated revenue of $727.27K.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-28 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-12 | $-0.91 | $-0.96 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $-0.86 | $-0.94 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.84 | $-0.93 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | N/A | N/A |
| Read Transcript | Q4 | 2020 | 2021-03-30 | N/A | N/A |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| February 27, 2025 | $-0.88 | $-0.92 | $- | $727.27K |
| November 12, 2024 | $-0.96 | $-0.91 | $- | $218.09K |
| August 08, 2024 | $-0.94 | $-0.86 | $399.00K | $510.00K |
| May 09, 2024 | $-0.93 | $-0.84 | $640.00K | $260.00K |
| February 28, 2024 | $-0.90 | $-0.89 | $- | $260.00K |
| November 07, 2023 | $-1.01 | $-0.89 | $346.00K | $190.00K |
| August 08, 2023 | $-0.94 | $-0.85 | $988.00K | $140.00K |
| May 04, 2023 | $-0.85 | $-0.82 | $2.68M | $630.00K |
| February 28, 2023 | $-0.84 | $-0.82 | $709.00K | $250.00K |
| November 14, 2022 | $-0.78 | $-0.78 | $458.00K | $250.00K |
| August 12, 2022 | $-0.81 | $-0.62 | $439.00K | $600.00K |
| May 12, 2022 | $-0.73 | $-0.56 | $3.13M | $5.20M |
| March 30, 2022 | $-0.68 | $-0.57 | $1.08M | $- |
| November 05, 2021 | $-0.73 | $-0.70 | $- | $- |
| August 10, 2021 | $-0.70 | $-0.60 | $- | $- |
| May 06, 2021 | $-0.69 | $-0.65 | $- | $- |
| March 30, 2021 | $-0.66 | $-0.58 | $0 | $- |
Annual Earnings
Annual Revenue
$1.04M
Fiscal Year 2024Annual Net Income
$-298.41M
Fiscal Year 2024Annual EPS
$-3.69
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-80.59M
Quarter Ending December 31, 2024EPS
$-0.88
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-7.22%
Year Ending December 31, 2024P/E Ratio
-13.84
Year Ending December 31, 2024Revenue Per Share
$0.01
Year Ending December 31, 2024Earnings Yield (TTM)
-10.07%
Trailing Twelve MonthsP/E Ratio (TTM)
-9.93
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.01
Trailing Twelve MonthsFrequently Asked Questions
Crinetics Pharmaceuticals's next earnings date is scheduled for May 08, 2025. The earnings call is expected to take place after market close.
In its last earnings report on February 27, 2025, Crinetics Pharmaceuticals reported earnings per share (EPS) of $-0.88, compared to an estimated EPS of $-0.92. The company reported revenue of $-, compared to an estimated revenue of $727.27K.
Crinetics Pharmaceuticals's current Price-to-Earnings (P/E) ratio is -13.84. The trailing twelve months (TTM) P/E ratio is -9.93. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Crinetics Pharmaceuticals reported total revenue of $1.04M and net income of $-298.41M. This represents a net profit margin of -287.2069297401.
Crinetics Pharmaceuticals's earnings yield is -7.22%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Crinetics Pharmaceuticals's return on equity (ROE) is -22.52%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Crinetics Pharmaceuticals's gross profit margin is 100.00%. This indicates that for every dollar of revenue, the company retains $1.00 as gross profit after accounting for the cost of goods sold.